Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accumulated Expenses: 2010-2022

Historic Accumulated Expenses for Cumberland Pharmaceuticals (CPIX) over the last 13 years, with Dec 2022 value amounting to $17.6 million.

  • Cumberland Pharmaceuticals' Accumulated Expenses rose 102.90% to $17.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $17.6 million, marking a year-over-year increase of 102.90%. This contributed to the annual value of $17.6 million for FY2022, which is 102.90% up from last year.
  • According to the latest figures from FY2022, Cumberland Pharmaceuticals' Accumulated Expenses is $17.6 million, which was up 102.90% from $8.7 million recorded in FY2021.
  • Over the past 5 years, Cumberland Pharmaceuticals' Accumulated Expenses peaked at $17.6 million during FY2022, and registered a low of $8.7 million during FY2021.
  • In the last 3 years, Cumberland Pharmaceuticals' Accumulated Expenses had a median value of $11.3 million in 2020 and averaged $12.5 million.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Accumulated Expenses plummeted by 33.67% in 2019 and then soared by 102.90% in 2022.
  • Cumberland Pharmaceuticals' Accumulated Expenses (Yearly) stood at $16.7 million in 2018, then crashed by 33.67% to $11.1 million in 2019, then increased by 1.53% to $11.3 million in 2020, then dropped by 22.98% to $8.7 million in 2021, then spiked by 102.90% to $17.6 million in 2022.